387 related articles for article (PubMed ID: 25023045)
1. Clinical, anthropometric, biochemical, and histological characteristics of nonobese nonalcoholic fatty liver disease patients of Bangladesh.
Alam S; Gupta UD; Alam M; Kabir J; Chowdhury ZR; Alam AK
Indian J Gastroenterol; 2014 Sep; 33(5):452-7. PubMed ID: 25023045
[TBL] [Abstract][Full Text] [Related]
2. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
[TBL] [Abstract][Full Text] [Related]
3. Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients.
Ampuero J; Ranchal I; Gallego-Durán R; Pareja MJ; Del Campo JA; Pastor-Ramírez H; Rico MC; Picón R; Pastor L; García-Monzón C; Andrade R; Romero-Gómez M
J Gastroenterol Hepatol; 2016 Sep; 31(9):1611-8. PubMed ID: 26946071
[TBL] [Abstract][Full Text] [Related]
4. The impact of body mass index on clinicopathological features of nonalcoholic fatty liver disease in Taiwan.
Lin CL; Tai CM; Huang JF; Liu CJ; Chen HF; Cheng PN; Chen CY; Peng CY; Wang CC; Weng SH; Tseng TC; Kao JH
J Gastroenterol Hepatol; 2022 Oct; 37(10):1901-1910. PubMed ID: 35790343
[TBL] [Abstract][Full Text] [Related]
5. Irisin in patients with nonalcoholic fatty liver disease.
Polyzos SA; Kountouras J; Anastasilakis AD; Geladari EV; Mantzoros CS
Metabolism; 2014 Feb; 63(2):207-17. PubMed ID: 24140091
[TBL] [Abstract][Full Text] [Related]
6. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
[No Abstract] [Full Text] [Related]
7. Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients.
Leung JC; Loong TC; Wei JL; Wong GL; Chan AW; Choi PC; Shu SS; Chim AM; Chan HL; Wong VW
Hepatology; 2017 Jan; 65(1):54-64. PubMed ID: 27339817
[TBL] [Abstract][Full Text] [Related]
8. Different predictors of steatosis and fibrosis severity among lean, overweight and obese patients with nonalcoholic fatty liver disease.
Shao C; Ye J; Li F; Feng S; Wang W; Zhong B
Dig Liver Dis; 2019 Oct; 51(10):1392-1399. PubMed ID: 30928418
[TBL] [Abstract][Full Text] [Related]
9. [Analysis of clinicopathological characteristics of non-alcoholic fatty liver disease].
Li J; Yang YF; Sun MM; Gong YY; Zhou HW; Zhang ZH
Zhonghua Bing Li Xue Za Zhi; 2023 May; 52(5):486-491. PubMed ID: 37106291
[No Abstract] [Full Text] [Related]
10. Clinical profile of non-alcoholic fatty liver disease in nonobese patients.
Lum JHM; Cheah MCC; Leow WQ; Wan WK; Lim TKH; Chow WC; Chang JPE; Goh GBB
J Gastroenterol Hepatol; 2021 Jan; 36(1):257-261. PubMed ID: 32557741
[TBL] [Abstract][Full Text] [Related]
11. Predictors of nonalcoholic steatohepatitis and significant fibrosis in non-obese nonalcoholic fatty liver disease.
Kim D; Kim W; Joo SK; Kim JH; Harrison SA; Younossi ZM; Ahmed A
Liver Int; 2019 Feb; 39(2):332-341. PubMed ID: 30298568
[TBL] [Abstract][Full Text] [Related]
12. What Is the Role of the New Index Relative Fat Mass (RFM) in the Assessment of Nonalcoholic Fatty Liver Disease (NAFLD)?
Machado MV; Policarpo S; Coutinho J; Carvalhana S; Leitão J; Carvalho A; Silva AP; Velasco F; Medeiros I; Alves AC; Bourbon M; Cortez-Pinto H
Obes Surg; 2020 Feb; 30(2):560-568. PubMed ID: 31637670
[TBL] [Abstract][Full Text] [Related]
13. Risk of obstructive sleep apnea with daytime sleepiness is associated with liver damage in non-morbidly obese patients with nonalcoholic fatty liver disease.
Pulixi EA; Tobaldini E; Battezzati PM; D'Ingianna P; Borroni V; Fracanzani AL; Maggioni M; Pelusi S; Bulgheroni M; Zuin M; Fargion S; Montano N; Valenti L
PLoS One; 2014; 9(4):e96349. PubMed ID: 24763757
[TBL] [Abstract][Full Text] [Related]
14. Characteristics of non-alcoholic steatohepatitis among lean patients in Japan: Not uncommon and not always benign.
Tobari M; Hashimoto E; Taniai M; Ikarashi Y; Kodama K; Kogiso T; Tokushige K; Takayoshi N; Hashimoto N
J Gastroenterol Hepatol; 2019 Aug; 34(8):1404-1410. PubMed ID: 30590868
[TBL] [Abstract][Full Text] [Related]
15. Increased serum concentration of ceramides in obese children with nonalcoholic fatty liver disease.
Wasilewska N; Bobrus-Chociej A; Harasim-Symbor E; Tarasów E; Wojtkowska M; Chabowski A; Lebensztejn DM
Lipids Health Dis; 2018 Sep; 17(1):216. PubMed ID: 30208901
[TBL] [Abstract][Full Text] [Related]
16. Nonalcoholic steatohepatitis in nonalcoholic fatty liver disease patients of Bangladesh.
Alam S; Noor-E-Alam SM; Chowdhury ZR; Alam M; Kabir J
World J Hepatol; 2013 May; 5(5):281-7. PubMed ID: 23717739
[TBL] [Abstract][Full Text] [Related]
17. Comparison of clinical and metabolic profiles of lean versus non-lean nonalcoholic fatty liver disease.
Navarroza AMC; Wong SN
Indian J Gastroenterol; 2021 Aug; 40(4):380-388. PubMed ID: 34213749
[TBL] [Abstract][Full Text] [Related]
18. Correlation between insulin resistance and liver histology in patients with nonalcoholic steatohepatitis with and without obesity.
Lazar MV; Eapen M; Nair HR; Siyad I; Gopalakrishna R
Indian J Gastroenterol; 2020 Feb; 39(1):42-49. PubMed ID: 32222944
[TBL] [Abstract][Full Text] [Related]
19. Differential progression of unhealthy diet-induced hepatocellular carcinoma in obese and non-obese mice.
Hymel E; Vlock E; Fisher KW; Farazi PA
PLoS One; 2022; 17(8):e0272623. PubMed ID: 35994501
[TBL] [Abstract][Full Text] [Related]
20. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M
Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
